/ Not yet recruiting临床2期IIT AMLM22/D3-The International Acute myeloid leukaemia (AML) Platform Consortium (IAPC) trial is a randomised, multi-arm study platform to compare the efficacy of experimental therapies versus standard of care in subjects with acute myeloid leukaemia in first complete remission. Domain 3 is investigating the safety and efficacy of an Astrazeneca drug labelled AZD5153 as a maintenance therapy option.
Evaluation Study of a New Management Strategy for Gastroesophageal Reflux Disease (GERD) - GMP
A Phase III, Randomised, Parallel Group, Multi-Centre Study in Recurrent Glioblastoma Patients to Compare the Efficacy of Cediranib [RECENTIN™, AZD2171] Monotherapy and the Combination of Cediranib with Lomustine to the Efficacy of Lomustine Alone - REGAL
100 项与 Astrazeneca Plc /Anti Infective Business/ 相关的临床结果
0 项与 Astrazeneca Plc /Anti Infective Business/ 相关的专利（医药）
100 项与 Astrazeneca Plc /Anti Infective Business/ 相关的药物交易
100 项与 Astrazeneca Plc /Anti Infective Business/ 相关的转化医学
